Northern Financial Advisors Inc Has $260,000 Holdings in Abbott Laboratories $ABT

Northern Financial Advisors Inc raised its position in shares of Abbott Laboratories (NYSE:ABT) by 10.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 1,914 shares of the healthcare product maker’s stock after purchasing an additional 186 shares during the quarter. Northern Financial Advisors Inc’s holdings in Abbott Laboratories were worth $260,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ABT. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories during the 1st quarter valued at approximately $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth approximately $28,000. Elequin Capital LP acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth approximately $30,000. JCIC Asset Management Inc. acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth approximately $32,000. Finally, Vision Financial Markets LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth approximately $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT opened at $133.05 on Wednesday. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The business’s fifty day moving average is $132.19 and its 200 day moving average is $131.45. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The stock has a market cap of $231.58 billion, a P/E ratio of 16.67, a P/E/G ratio of 2.54 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same period last year, the business earned $1.14 EPS. The business’s revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ABT. Royal Bank Of Canada raised their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 15th. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and raised their price objective for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Mizuho raised their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 16th. Weiss Ratings reiterated a “buy (b)” rating on shares of Abbott Laboratories in a report on Saturday, September 27th. Finally, William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $146.24.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.